Viking Fund Management LLC Has $16.68 Million Position in AbbVie Inc. $ABBV

Viking Fund Management LLC lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,000 shares of the company’s stock after selling 4,000 shares during the quarter. AbbVie accounts for about 1.9% of Viking Fund Management LLC’s investment portfolio, making the stock its 9th biggest holding. Viking Fund Management LLC’s holdings in AbbVie were worth $16,680,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ABBV. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie during the second quarter valued at approximately $26,000. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter worth approximately $26,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie in the 3rd quarter worth approximately $31,000. Caitlin John LLC bought a new stake in AbbVie in the 3rd quarter worth approximately $33,000. Finally, Delos Wealth Advisors LLC purchased a new stake in AbbVie during the 2nd quarter valued at $39,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Down 0.0%

ABBV stock opened at $204.86 on Wednesday. The business’s 50-day moving average price is $222.48 and its 200-day moving average price is $224.74. The stock has a market cap of $362.23 billion, a P/E ratio of 86.81, a PEG ratio of 0.71 and a beta of 0.34. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the firm posted $2.16 EPS. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.08% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Citigroup dropped their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and upped their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.